We are delighted that the Scottish Medicines Consortium has approved the use of Saxenda for patients living with obesity, pre-diabetes and at high cardiovascular risk.
This will have a positive impact on this group of patients and increase treatment choices. The decision will also be an impetus for change in the way that obesity care is provided in Scotland. Obesity services will have to be funded in order to have the appropriate resources to provide obesity pharmacotherapy as part of a standardised treatment pathway. Such a pathway can serve as a pilot and framework for the use of even more effective pharmacotherapy options that will become available in the near future.
The relevant Detailed Advice Document can be found here and a link to the Decision Explained public information summary can be found here.